Antibody therapy for non-Hodgkin's lymphoma

Research output: Contribution to journalReview articlepeer-review

1 Scopus citations


Significant advances in the therapy of non-Hodgkin's lymphoma have been made with the introduction of monoclonal antibodies. The anti-CD20 antibody rituximab has become standard as monotherapy in patients with indolent lymphoma, and in combination with chemotherapy in patients with aggressive lymphoma. A number of new monoclonal antibodies targeting different molecules on lymphoma cells are now in clinical development and show promise both as single agents and in combination therapy. Furthermore, anti-CD20 monoclonal antibodies have been radioconjugated to increase their efficacy. Future studies will therefore be needed to explore the efficacy of combinations of these agents and to develop a rational strategy for their use.

Original languageEnglish (US)
Pages (from-to)175-181
Number of pages7
JournalCurrent Opinion in Molecular Therapeutics
Issue number2
StatePublished - Apr 2004


  • Antibody-dependent cellular cytotoxicity
  • Apoptosis
  • Complement
  • Monoclonal antibody
  • Non-Hodgkin's lymphoma
  • Radioimmunoconjugate therapy

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics
  • Pharmacology
  • Drug Discovery
  • Genetics(clinical)


Dive into the research topics of 'Antibody therapy for non-Hodgkin's lymphoma'. Together they form a unique fingerprint.

Cite this